Market Research Report
Biologics Market Trends and Forecasts 2018-2028
|Published by||Visiongain Ltd||Product code||235218|
|Published||Content info||303 Pages
Delivery time: 1-2 business days
|Biologics Market Trends and Forecasts 2018-2028|
|Published: November 14, 2018||Content info: 303 Pages||
BIOLOGICS MARKET TRENDS AND FORECASTS 2018-2028
Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.
The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 303-page report you will receive 166 charts- all unavailable elsewhere.
The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Analysis and forecast from 2018-2028 for selected leading biologics in the market:
This report provides individual revenue forecasts from 2018-2028 for these national markets:
Our study discusses the selected leading companies that are the major players in the biologics market:
This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.
This report discusses the SWOT and STEP Analysis of the biologics market.
Visiongain's study is intended for anyone requiring commercial analyses for the biologics market. You find data, trends and predictions.
Buy our report today ‘Biologics Market Trends and Forecasts 2018-2028: Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies’.
Visiongain is a trading partner with the US Federal Government.